A Phase 3 interventional study of Fitusiran and BPA prophylaxis in Hemophilia, sponsored by Genzyme, a Sanofi Company. Completed at 35 sites in 15 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.
Among the 10 studies testing fitusiran in Hemophilia A, this one is the 5th largest by enrollment, is one of 3 that started in 2018, is one of 6 in phase 3, and was the 5th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Belgium, Brazil and 9 more countries
Ages 1–11 · Men only
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
By country, each count listing its studies:
fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 7 · Phase 4 1
First in 2014; this study’s year is marked. 3 started in 2018.
This study's enrollment of 80 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 70 across the 10 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
29 studies in Hemophilia A by Sanofi: 4 open now, 8 under way, 3 of them phase 3. Of 21 finished, 14 (67%) have results posted.
Among the 29 studies in Hemophilia A by Sanofi, this one is the 10th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2018, is one of 14 in phase 3, and was the 15th registered.
Sanofi’s Hemophilia A studies by the year they started, since 2009.
1 of the studies testing fitusiran in Hemophilia A that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05662319Phase 3SanofiA Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia | 2027-03-25 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing fitusiran in Hemophilia A, from their registry updates:
Among Sanofi’s 29 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To characterize the frequency of bleeding episodes (BE) while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor concentrate or bypassing agent (BPA) prophylaxis.
Secondary Objectives:
The estimated total time on study, inclusive of Screening, for each participant was up to 15 months for participants who were enrolled in the extension study except for participants in the subgroup of Cohort A, for whom it was up to 9 months. The estimated total time on study was up to 21 months (up to 15 months in participants in the subgroup of Cohort A) in participants who did not enroll in the extension study due to the requirement for an additional up to 6 months of follow-up for monitoring of antithrombin (AT) levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subgroup of participants in Cohort A participants might additionally meet the following criteria to be eligible to start treatment with fitusiran directly after the screening period:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort A \[inhibitor\]: participants with severe hemophilia A/B and inhibitory antibodies to coagulation factor VIII (FVIII)/factor IX (FIX) previously received BPA prophylaxis. Cohort B \[non-inhibitor\]: participants with severe hemophilia A/B without inhibitory antibodies to FVIII/FIX previously received factor prophylaxis. Participants from both cohorts was enrolled into 6-month factor/BPA prophylaxis period and continued their pre-study, regularly scheduled prophylaxis regimen with factor/BPAs. This period could be skipped by subgroup of Cohort A (hemophilia B with inhibitors to FIX and historical annualized bleeding rate \[ABR\] \>=20) that started directly with fitusiran. Post completing factor/BPA prophylaxis period, participants entered 7-month fitusiran treatment period (1-month onset+6-month efficacy) followed by AT follow-up/roll-over into LTE15174 (NCT03754790). Throughout study, participants could receive on-demand treatment for breakthrough BE with factor/BPAs, as appropriate.
Drug: Fitusiran · Drug: BPA prophylaxis · Drug: Factor (FVIII or FIX) prophylaxis
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Pharmaceutical form: solution for injection Route of administration: Intravenous
Pharmaceutical form: solution for injection Route of administration: Intravenous
Estimated Annualized Bleeding Rate (ABR)
Bleeding episodes (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/total number of days in the respective period\*365.25. Estimated data were derived by using repeated measures negative binomial (NB) regression model.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Observed Annualized Bleeding Rate (ABR)
A bleeding episode (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as 1 BE towards ABR. Any bleeding that began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/number of days in the respective period \*365.25.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Estimated Annualized Spontaneous Bleeding Rate
BE: any occurrence of hemorrhage that might require administration of factor/BPA infusion. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. Spontaneous BE: BE occurrence for no apparent/known reason, particularly into joints, muscles, and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data was derived using repeated measures NB regression model.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Observed Annualized Spontaneous Bleeding Rate
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Spontaneous BE: bleeding event occurred for no apparent or known reason, particularly into joints, muscles and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Estimated Annualized Joint Bleeding Rate
BE: any hemorrhage that required administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection to treat BE at that location was considered part of original BE; counted as 1 BE towards ABR. Bleeding after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint ("aura") + increasing swelling/warmth over joint skin, increasing pain/progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data were derived by using repeated measures NB regression model.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Observed Annualized Joint Bleeding Rate
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint (aura) increasing swelling/warmth over joint skin, increasing pain or progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of joint BE/number of days in respective period\*365.25.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Change in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period
Haem-A-QoL: participant-reported questionnaire for adults aged \>=17 years with hemophilia and comprised of 46 items covering 10 domains. Physical health domain (PHD) is assessed with 5 items rated on 5-point Likert scale: never, rarely, sometimes, often or all the time. Raw score for PHD were transformed to scale ranged from 0 to 100, where lower scores = better physical health. Least square (LS) mean and 95% confidence interval (CI) by mixed model for repeated measure (MMRM) analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.
Time frame: Month -6 of Factor or BPA prophylaxis period (Baseline), Day 1 (Month 1) and Month 7 of fitusiran treatment period
Change in Haemophilia Quality of Life Questionnaire for Adults Total Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period
Haem-A-QoL: questionnaire for adults aged \>= 17 years with hemophilia; and comprised of 46 items covering 10 domains: physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality. Items were rated on 5-point Likert scale: never, rarely, sometimes, often or all time. Domain raw score was transformed to scale ranged from 0 to 100, where lower scores=better health. LS mean \& 95% CI by MMRM analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.
Time frame: Month -6 of Factor or BPA prophylaxis period (Baseline), Day 1 (Month 1) and Month 7 of fitusiran treatment period
Estimated Annualized Bleeding Rate in the Fitusiran Onset Period
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Estimated ABR and 95% CI was derived by using repeated measures NB regression model with logarithm of duration (years) that each participant spends in 1-Month fitusiran onset period matching BE data being analyzed as offset variable. ABR = total number of qualifying BE/number of days in respective period \*365.25.
Time frame: Day 1 up to Day 28 or up to the last day of bleeding follow up (any day up to Day 28), whichever was earliest
Observed Annualized Bleeding Rate in the Fitusiran Onset Period
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and was counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in the 1-month onset period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in 1-month onset period and excluded any bleeding events in period of intercurrent events.
Time frame: Day 1 up to Day 28 or up to the last day of bleeding follow up (any day up to Day 28), whichever was earliest
Estimated Annualized Bleeding Rate in the Fitusiran Treatment Period
BE: defined as any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in the period of intercurrent events. ABR = total number of qualifying BE/number of days in respective period \*365.25.
Time frame: From Day 1 up to Day 190
Observed Annualized Bleeding Rate in the Fitusiran Treatment Period
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original bleeding event and was counted as one BE towards ABR. Any bleeding that began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in treatment period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in period of intercurrent events.
Time frame: from Day 1 up to Day 190
Cohort A: Annualized Weight-adjusted Consumption of BPA (Activated Prothrombin Complex Concentrates)
Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: \[Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period\]\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agent: aPCC (unit per kilogram \[U/kg\]) were reported.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Cohort A: Annualized Weight-adjusted Consumption of BPA (Recombinant Factor VIIa)
Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: rFVIIa (unit: micrograms per kg \[mcg/kg\]) were reported. Combined data of annualized weight-adjusted BPA consumption (mcg/kg) for both treated bleeds and prophylaxis purpose were reported in this outcome measure.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Cohort B: Annualized Weight-adjusted Consumption of Factor
Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: FVIII and FIX (unit: international Units \[IU\] per kg \[IU/kg\]) were reported.
Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Study was conducted at 35 active sites in 15 countries. Total of 99 participants were screened from 25 July 2018 to 19 March 2021, of which 19 were screen failure due to not meeting eligibility criteria. Study had 2 main periods: 6-month factor/bypassing agent (BPA) prophylaxis period \& 7-month fitusiran treatment period (1-month onset and 6-month fitusiran efficacy period).
| Milestone | Cohort A: Inhibitor | Cohort B: Non-inhibitor |
|---|---|---|
| Started | 30 | 50 |
| Started directly with fitusiran | 2 | 0 |
| Started with factor or bpa prophylaxis | 28 | 50 |
| Completed | 23 | 46 |
| Not completed | 7 | 4 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Parent withdrew consent | 1 | 0 |
| Withdrew: Switched to treatment not per protocol | 4 | 0 |
| Withdrew: Related to coronavrus disease 2019 | 1 | 0 |
| Withdrew: Did not meet trial eligibility | 0 | 2 |
| Milestone | Cohort A: Inhibitor | Cohort B: Non-inhibitor |
|---|---|---|
| Started | 23 | 46 |
| Received 80mg qm & part of safety analysis set 1 (sas 1) | 21 | 46 |
| Received 50 mg q2m & part of safety analysis set 2 (sas 2) | 2 | 0 |
| Efficacy analysis set 1 (eas 1) | 19 | 46 |
| Efficacy analysis set 2 (eas 2) | 2 | 0 |
| Completed | 17 | 37 |
| Not completed | 6 | 9 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: More than 1 antithrombin (at) measurement less than 15% | 1 | 0 |
| Withdrew: Study drug on hold | 4 | 5 |
| Withdrew: Participant's decision | 0 | 2 |
| Withdrew: Adverse event | 0 | 2 |
Bleeding episodes (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/total number of days in the respective period\*365.25. Estimated data were derived by using repeated measures negative binomial (NB) regression model.
| episodes per participant per year | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Efficacy Period |
|---|---|---|
| Estimated Annualized Bleeding Rate (ABR) | 7.482 (5.520 to 10.141) | 2.908 (1.727 to 4.898) |
A bleeding episode (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as 1 BE towards ABR. Any bleeding that began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/number of days in the respective period \*365.25.
| episodes per participant per year | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Efficacy Period |
|---|---|---|
| Observed Annualized Bleeding Rate (ABR) | 7.56 ± 9.49 | 3.19 ± 7.75 |
BE: any occurrence of hemorrhage that might require administration of factor/BPA infusion. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. Spontaneous BE: BE occurrence for no apparent/known reason, particularly into joints, muscles, and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data was derived using repeated measures NB regression model.
| episodes per participant per year | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Efficacy Period |
|---|---|---|
| Estimated Annualized Spontaneous Bleeding Rate | 5.002 (3.424 to 7.305) | 2.222 (1.190 to 4.152) |
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Spontaneous BE: bleeding event occurred for no apparent or known reason, particularly into joints, muscles and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25.
| episodes per participant per year | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Efficacy Period |
|---|---|---|
| Observed Annualized Spontaneous Bleeding Rate | 5.09 ± 7.93 | 2.51 ± 7.33 |
BE: any hemorrhage that required administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection to treat BE at that location was considered part of original BE; counted as 1 BE towards ABR. Bleeding after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint ("aura") + increasing swelling/warmth over joint skin, increasing pain/progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data were derived by using repeated measures NB regression model.
| episodes per participant per year | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Efficacy Period |
|---|---|---|
| Estimated Annualized Joint Bleeding Rate | 5.282 (3.647 to 7.651) | 2.564 (1.440 to 4.566) |
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint (aura) increasing swelling/warmth over joint skin, increasing pain or progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of joint BE/number of days in respective period\*365.25.
| episodes per participant per year | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Efficacy Period |
|---|---|---|
| Observed Annualized Joint Bleeding Rate | 5.35 ± 8.19 | 2.82 ± 7.54 |
Haem-A-QoL: participant-reported questionnaire for adults aged \>=17 years with hemophilia and comprised of 46 items covering 10 domains. Physical health domain (PHD) is assessed with 5 items rated on 5-point Likert scale: never, rarely, sometimes, often or all the time. Raw score for PHD were transformed to scale ranged from 0 to 100, where lower scores = better physical health. Least square (LS) mean and 95% confidence interval (CI) by mixed model for repeated measure (MMRM) analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.
| score on a scale | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Treatment Period |
|---|---|---|
| Change in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period | -6.00 (-10.19 to -1.81) | -9.60 (-15.35 to -3.84) |
Haem-A-QoL: questionnaire for adults aged \>= 17 years with hemophilia; and comprised of 46 items covering 10 domains: physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality. Items were rated on 5-point Likert scale: never, rarely, sometimes, often or all time. Domain raw score was transformed to scale ranged from 0 to 100, where lower scores=better health. LS mean \& 95% CI by MMRM analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.
| score on a scale | Overall Factor/BPA Prophylaxis Period | Overall Fitusiran 80 mg Treatment Period |
|---|---|---|
| Change in Haemophilia Quality of Life Questionnaire for Adults Total Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period | -3.07 (-5.56 to -0.58) | -7.62 (-10.26 to -4.98) |
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Estimated ABR and 95% CI was derived by using repeated measures NB regression model with logarithm of duration (years) that each participant spends in 1-Month fitusiran onset period matching BE data being analyzed as offset variable. ABR = total number of qualifying BE/number of days in respective period \*365.25.
| episodes per participant per year | Overall Fitusiran 80 mg 1-Month Onset Period |
|---|---|
| Estimated Annualized Bleeding Rate in the Fitusiran Onset Period | 5.419 (3.716 to 7.901) |
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and was counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in the 1-month onset period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in 1-month onset period and excluded any bleeding events in period of intercurrent events.
| episodes per participant per year | Overall Fitusiran 80 mg 1-Month Onset Period |
|---|---|
| Observed Annualized Bleeding Rate in the Fitusiran Onset Period | 5.42 ± 8.28 |
BE: defined as any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in the period of intercurrent events. ABR = total number of qualifying BE/number of days in respective period \*365.25.
| episodes per participant per year | Overall Fitusiran 80 mg Treatment Period |
|---|---|
| Estimated Annualized Bleeding Rate in the Fitusiran Treatment Period | 3.317 (2.111 to 5.211) |
BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original bleeding event and was counted as one BE towards ABR. Any bleeding that began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in treatment period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in period of intercurrent events.
| episodes per participant per year | Overall Fitusiran 80 mg Treatment Period |
|---|---|
| Observed Annualized Bleeding Rate in the Fitusiran Treatment Period | 3.48 ± 6.98 |
Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: \[Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period\]\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agent: aPCC (unit per kilogram \[U/kg\]) were reported.
| U/kg per participant per year | BPA Prophylaxis: Cohort: A Inhibitor | Fitusiran 80 mg Prophylaxis: Cohort A: Inhibitor |
|---|---|---|
| Cohort A: Annualized Weight-adjusted Consumption of BPA (Activated Prothrombin Complex Concentrates) | 7912.7 ± 5507.6 | 39.7 ± 87.0 |
Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: rFVIIa (unit: micrograms per kg \[mcg/kg\]) were reported. Combined data of annualized weight-adjusted BPA consumption (mcg/kg) for both treated bleeds and prophylaxis purpose were reported in this outcome measure.
| mcg/kg per participant per year | BPA Prophylaxis: Cohort: A Inhibitor | Fitusiran 80 mg Prophylaxis: Cohort A: Inhibitor |
|---|---|---|
| Cohort A: Annualized Weight-adjusted Consumption of BPA (Recombinant Factor VIIa) | 18895.8 ± 14081.9 | 168.8 ± 290.8 |
Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: FVIII and FIX (unit: international Units \[IU\] per kg \[IU/kg\]) were reported.
| IU/kg per participant per year | Factor Prophylaxis: Cohort B: Non-inhibitor | Fitusiran 80 mg Prophylaxis: Cohort B: Non-inhibitor |
|---|---|---|
| FVIII | 3396.9 ± 1144.5 | 60.7 ± 148.3 |
| FIX | 3175.5 ± 961.3 | 17.8 ± 56.1 |
Collected over Factor/BPA prophylaxis period: from Day -168 to Day -1; Fitusiran 80 mg QM/50 mg Q2M period: from Day 1 of fitusiran treatment period (i.e., 1 month onset+ 6 months efficacy) until AT follow up (i.e. up to 21 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: SAS 1 - BPA Prophylaxis | 0/19 (0%) | 5/19 (26.3%) | 10/19 (52.6%) |
| Cohort A: SAS 1 - Fitusiran 80 mg QM | 0/21 (0%) | 5/21 (23.8%) | 13/21 (61.9%) |
| Cohort B: SAS 1 - Factor Prophylaxis | 0/46 (0%) | 0/46 (0%) | 9/46 (19.6%) |
| Cohort B: SAS 1 - Fitusiran 80 mg QM | 0/46 (0%) | 4/46 (8.7%) | 28/46 (60.9%) |
| Overall: SAS 1 - Factor/BPA Prophylaxis | 0/65 (0%) | 5/65 (7.7%) | 19/65 (29.2%) |
| Overall: SAS 1 - Fitusiran 80 mg QM | 0/67 (0%) | 9/67 (13.4%) | 41/67 (61.2%) |
| Cohort A: SAS 2 - BPA Prophylaxis | 0/2 (0%) | 1/2 (50%) | 1/2 (50%) |
| Cohort A: SAS 2 - Fitusiran 50 mg Q2M | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Event | Cohort A: SAS 1 - BPA Prophylaxis | Cohort A: SAS 1 - Fitusiran 80 mg QM | Cohort B: SAS 1 - Factor Prophylaxis | Cohort B: SAS 1 - Fitusiran 80 mg QM | Overall: SAS 1 - Factor/BPA Prophylaxis | Overall: SAS 1 - Fitusiran 80 mg QM | Cohort A: SAS 2 - BPA Prophylaxis | Cohort A: SAS 2 - Fitusiran 50 mg Q2M |
|---|---|---|---|---|---|---|---|---|
| HaemarthrosisMusculoskeletal and connective tissue disorders | 1/19 | 0/21 | 0/46 | 0/46 | 1/65 | 0/67 | 1/2 | 0/2 |
| Covid-19 PneumoniaInfections and infestations | 0/19 | 0/21 | 0/46 | 0/46 | 0/65 | 0/67 | 0/2 | 1/2 |
| Haemophilic ArthropathyMusculoskeletal and connective tissue disorders | 2/19 | 1/21 | 0/46 | 1/46 | 2/65 | 2/67 | 0/2 | 0/2 |
| Muscle HaemorrhageMusculoskeletal and connective tissue disorders | 1/19 | 0/21 | 0/46 | 0/46 | 1/65 | 0/67 | 0/2 | 0/2 |
| GastroenteritisInfections and infestations | 1/19 | 0/21 | 0/46 | 0/46 | 1/65 | 0/67 | 0/2 | 0/2 |
| FallInjury, poisoning and procedural complications | 0/19 | 1/21 | 0/46 | 0/46 | 0/65 | 1/67 | 0/2 | 0/2 |
| Femur FractureInjury, poisoning and procedural complications | 0/19 | 1/21 | 0/46 | 0/46 | 0/65 | 1/67 | 0/2 | 0/2 |
| Pancreatitis AcuteGastrointestinal disorders | 0/19 | 1/21 | 0/46 | 0/46 | 0/65 | 1/67 | 0/2 | 0/2 |
| Central Venous Catheter RemovalSurgical and medical procedures | 0/19 | 1/21 | 0/46 | 0/46 | 0/65 | 1/67 | 0/2 | 0/2 |
| CholelithiasisHepatobiliary disorders | 0/19 | 1/21 | 0/46 | 0/46 | 0/65 | 1/67 | 0/2 | 0/2 |
| Event | Cohort A: SAS 1 - BPA Prophylaxis | Cohort A: SAS 1 - Fitusiran 80 mg QM | Cohort B: SAS 1 - Factor Prophylaxis | Cohort B: SAS 1 - Fitusiran 80 mg QM | Overall: SAS 1 - Factor/BPA Prophylaxis | Overall: SAS 1 - Fitusiran 80 mg QM | Cohort A: SAS 2 - BPA Prophylaxis | Cohort A: SAS 2 - Fitusiran 50 mg Q2M |
|---|---|---|---|---|---|---|---|---|
| ToothacheGastrointestinal disorders | 0/19 | 1/21 | 0/46 | 1/46 | 0/65 | 2/67 | 0/2 | 2/2 |
| Fibrin D Dimer IncreasedInvestigations | 0/19 | 3/21 | 0/46 | 2/46 | 0/65 | 5/67 | 0/2 | 1/2 |
| Lymphocyte Count IncreasedInvestigations | 0/19 | 0/21 | 0/46 | 0/46 | 0/65 | 0/67 | 1/2 | 0/2 |
| Neutrophil Count DecreasedInvestigations | 0/19 | 0/21 | 0/46 | 0/46 | 0/65 | 0/67 | 1/2 | 0/2 |
| White Blood Cell Count DecreasedInvestigations | 0/19 | 0/21 | 0/46 | 0/46 | 0/65 | 0/67 | 1/2 | 0/2 |
| HaemorrhoidsGastrointestinal disorders | 0/19 | 0/21 | 0/46 | 0/46 | 0/65 | 0/67 | 1/2 | 0/2 |
| Alanine Aminotransferase IncreasedInvestigations | 1/19 | 3/21 | 0/46 | 15/46 | 1/65 | 18/67 | 0/2 | 0/2 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/19 | 4/21 | 1/46 | 2/46 | 4/65 | 6/67 | 0/2 | 0/2 |
| NasopharyngitisInfections and infestations | 0/19 | 1/21 | 1/46 | 7/46 | 1/65 | 8/67 | 0/2 | 0/2 |
| FallInjury, poisoning and procedural complications | 2/19 | 0/21 | 0/46 | 0/46 | 2/65 | 0/67 | 0/2 | 0/2 |
Baseline analysis population included all completed participants from BPA/factor prophylaxis period + 2 participants from Cohort A subgroup who directly enrolled to fitusiran treatment period.
| Age, Continuous(years) | Cohort A: Inhibitor | Cohort B: Non-inhibitor | Total Title |
|---|---|---|---|
| Mean | 27.7 ± 15.9 | 23.5 ± 7.3 | 24.9 ± 11.0 |
| Sex: Female, Male(Participants) | Cohort A: Inhibitor | Cohort B: Non-inhibitor | Total Title |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 23 | 46 | 69 |
| Race (NIH/OMB)(Participants) | Cohort A: Inhibitor | Cohort B: Non-inhibitor | Total Title |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 17 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 18 | 27 | 45 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2018 to primary completion in Jan 2022, 41 months.
Results were first posted in Feb 2023, 1 year after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 41 months is above that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fitusiran